Cns Pharmaceuticals, Inc. · NASDAQ:CNSP
Cns Pharmaceuticals — Investor Presentation (July 2021)
19 slides from Cns Pharmaceuticals's investor presentation, Jul 19, 2021
Slide 1: CNS Pharmaceuticals Investor Presentation July 2021
www.cnspharma.com 2100 West Loop South, Suite 900 Houston, TX 77027 (800) 946 - 9185 NASDAQ: CNSP July 2021
Slide 2: Forward-Looking Statements
CNS pharmaceuticals Forward - Looking Statements This presentation incorporates information from materials filed with the SEC and contains forward - looking statements . All statements contained herein other than statements of historical fact, including statements regarding our future results of ope
Slide 3: Investment Highlights
CNS pharmaceuticals Investment Highlights • Developing anti - cancer drug candidates for the treatment of primary and metastatic brain and CNS cancer • Two lead programs initially developed by Dr. Waldemar Priebe, Professor of Medicinal Chemistry at The University of Texas MD Anderson Cancer Center
Slide 4: Oncology Pipeline
CNS pharmaceuticals Oncology Pipeline PRODUCT SPONSOR INDICATION RESEARCH PRECLINICAL PHASE 1 PHASE 2 Berubicin CNS GBM (Global, adults) Berubicin WPD GBM (EU, adults) Q2 2021 Berubicin WPD GBM (EU, pediatric) H2 2021 Berubicin CNS CNS Lymphoma, Metastatic Lung & Breast 2021 - 2022 WP1244 CNS CNS tu
Slide 5: Management Team
CNS pharmaceuticals Distinctive record of business successes and more than 15 years of experience managing the operations, strategies and finances of public and private companies. PRESIDENT & CHIEF EXECUTIVE OFFICER John M. Climaco , Esq Board certified hematologist/medical oncologist with extensive
Slide 6: Dr. Priebe and Advisors
CNS pharmaceuticals Dr. Priebe is a Professor of Medicinal Chemistry in the Section of Immunobiology and Drug Carriers in the Department of Bioimmunotherapy at The University of Texas MD Anderson Cancer Center. Dr. Priebe is the inventor of more than 50 patents and the author of more than 200 scient
Slide 7: Glioblastoma Multiforme (GBM)
CNS pharmaceuticals Glioblastoma Multiforme (GBM) 1: https://braintumor.org/take - action/about - gbm/ One of the most aggressive, deadly and treatment - resistant cancers that forms in the brain Current standard of care ineffective in ~60% of patients 12 - 18 months: Average life expectancy 1 Can a
Slide 8: Lead Compound: Berubicin
CNS pharmaceuticals 8 x 44% OF PHASE 1 PATIENTS OBTAINED CLINICAL BENEFIT OF STABLE DISEASE OR BETTER x ONE COMPLETE RESPONDER FROM PHASE 1 REMAINS CANCER - FREE APPROXIMATELY 14 YEARS FOLLOWING TREATMENT • Initiated potentially pivotal study in lead indication, glioblastoma, in May 2021 • Entering
Slide 9: Berubicin Crosses the Blood-Brain Barrier
CNS pharmaceuticals BERUBICIN IS THE FIRST ANTHRACYCLINE TO APPEAR TO CROSS THE BLOOD - BRAIN BARRIER AND IS DESIGNED TO CONCENTRATE IN TUMOR TISSUE WITHIN THE BRAIN Berubicin for the Treatment of GBM Mechanism of Action Selective update in tumor tissue and high brain concentration provides potentia
Slide 10: Demonstrated Clinical Response in GBM
CNS pharmaceuticals Demonstrated Clinical Response in GBM * This does not always mean the cancer is cured. Also called a complete remission: www.cancer.gov/publications/dictionaries/cancer - terms/def/complete - response 6 MO. POST - TREATMENT Berubicin Phase 1 Results PRE - TREATMENT • 44% subjects
Slide 11: Potentially Pivotal Study
CNS pharmaceuticals 11 Potentially Pivotal Study • Dose Berubicin 7.1 mg/m2 IV infusion vs. Lomustine 130 mg/m2 oral • Clinical Sites ~60 centers across; North America, Europe and Asia Pacific • Primary Endpoint Overall Survival (OS) • Secondary Endpoints Duration of Response ( DoR ); Objective Resp
Slide 12: Open Label Phase 2 Study in Europe
CNS pharmaceuticals Open Label Phase 2 Study in Europe Adult Study Expected to Commence H2 2021 FULLY GRANT FUNDED ($6M) AT NO COST TO CNS PHARMA CONDUCTED BY EUROPEAN PARTNER, WPD PHARMACEUTICALS • Dose Berubicin 7.1 mg/m2 IV infusion • Primary Endpoint Overall Survival (OS) • Secondary Endpoints D
Slide 13: Expansion Into Other Cancers
CNS pharmaceuticals 13 Expansion Into Other Cancers INDICATION PATIENT POPULATION ESTIMATED SIZE COMMENTS Primary Brain Tumors Relapsed High Grade Gliomas 15,000 Existing data in this population Brain Metastases - Combination with Radiation Therapy Small Cell Lung Cancer 56,500 Anthracycline sensiti
Slide 14: WP1244
CNS pharmaceuticals 14 WP1244 TECHNOLOGY ORIGINALLY DEVELOPED AND LICENSED FROM THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER • Believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation • Target Indications: • Brain cancers • Pancreatic • Ovarian • Lymphomas • Tech
Slide 15: Corporate Overview
CNS pharmaceuticals 15 Corporate Overview
Slide 16: Financial Snapshot
CNS pharmaceuticals Financial Snapshot Market Cap 1 ~$47M 1. As of June 30, 2021 NASDAQ: CNSP IPO $9.8M November 7, 2019 Shares Outstanding ~23.9M Average Volume 1 ~455K Cash Balance $11M As of March 31, 2021
Slide 17: Value Driving Milestones
CNS pharmaceuticals 17 Value Driving Milestones • Berubicin Development in the U.S. x Orphan Drug Designation June 2020 x IND Accepted for Berubicin Dec. 2020 x Initiated Potentially Pivotal Global Berubicin trial for GBM May 2021 x Fast Track Designation June 2021 Patient Dosing in Potentially Pivo
Slide 18: Investment Summary
CNS pharmaceuticals Investment Summary DEVELOPING A PIPELINE OF ANTI - CANCER DRUG CANDIDATES FOR THE TREATMENT OF BRAIN CANCERS, AN AREA IN NEED OF NEW INNOVATIONS Multiple value - driving milestones expected throughout 2021 1 Lead program, Berubicin , in ongoing potentially pivotal study; entering
Slide 19: www.cnspharma.com 2100 West Loop South, Suite Houston, TX 77027 (800) 946 - 9185
www.cnspharma.com 2100 West Loop South, Suite 900 Houston, TX 77027 (800) 946 - 9185 NASDAQ: CNSP
CNS Pharmaceuticals — Investor Presentation (July 2021) on 6ix